https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-07-27 / Ther Apher Dial 2020 Oct;24(5):482-491
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-07-27 / Ther Apher Dial 2020 Oct;24(5):482-4912020-07-27 00:00:002021-05-19 14:28:19Immunotherapy employing dendritic cell vaccination for patients with advanced or relapsed esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-05-17 / Oncol Lett 2018 Jul;16(1):1348-1356
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-05-17 / Oncol Lett 2018 Jul;16(1):1348-13562018-05-17 00:00:002021-05-19 14:28:20Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-01-26 / J Clin Oncol 36, 2018 (suppl 5S; abstr 96)2018-01-26 11:47:012021-05-19 14:28:45Autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: An analysis of immunological responses.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-23 / J Clin Oncol 35, 2017 (suppl 7S; abstract 153)2017-02-23 11:47:542021-05-19 14:29:04Safety, efficacy, and immunogenicity of autologous tumor lysate-pulsed dendritic cell vaccination therapy after resection of stage IIA (T2N0, T3N0) esophageal cancer: A phase I trial.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-02-01 / J. Immunother. 2017 Feb/Mar;40(2):71-762017-02-01 00:00:002019-02-15 08:52:03A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-25 / J Clin Pharm Ther 2017 Apr;42(2):155-164
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-25 / J Clin Pharm Ther 2017 Apr;42(2):155-1642017-01-25 00:00:002017-01-25 00:00:00Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-01-17 / Oncotarget 2017 Jan;8(3):5339-5348
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-01-17 / Oncotarget 2017 Jan;8(3):5339-53482017-01-17 00:00:002017-01-17 00:00:00Regional hyperthermia combined with radiotherapy for esophageal squamous cell carcinoma with supraclavicular lymph node metastasis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-11-01 / Cell Rep 2016 11;17(6):1621-1631
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-11-01 / Cell Rep 2016 11;17(6):1621-16312016-11-01 00:00:002016-11-01 00:00:00Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-09-08 / Oncol. Rep. 2015 Nov;34(5):2656-64
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-09-08 / Oncol. Rep. 2015 Nov;34(5):2656-642015-09-08 00:00:002019-02-15 09:33:31Hyperthermia induces apoptosis by targeting Survivin in esophageal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-303
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2015-04-01 / Anticancer Res. 2015 Apr;35(4):2299-3032015-04-01 00:00:002015-04-01 00:00:00Hyperthermia combined with chemotherapy for patients with residual or recurrent oesophageal cancer after definitive chemoradiotherapy
